Clear All
11765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
55154-0450-05 55154-0450 Metoclopramide Hydrochloride Metoclopramide Hydrochloride 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Dec 10, 1993 In Use
00703-4502-93 00703-4502 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Sep 4, 2024 In Use
55154-2353-08 55154-2353 METOCLOPRAMIDE Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Sep 22, 2009 Feb 28, 2019 In Use
51662-1367-01 51662-1367 Metoclopramide Metoclopramide 10.0 mg/2mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Oct 14, 2019 In Use
83634-0779-02 83634-0779 Metoclopramide hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Jun 30, 2024 In Use
70934-0548-30 70934-0548 Metoclopramide Metoclopramide 10.0 mg/1 Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Oral Feb 26, 2020 In Use
42292-0051-05 42292-0051 Erlotinib hydrochloride Erlotinib Hydrochloride 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 28, 2019 Jan 31, 2021 No Longer Used
55513-0955-01 55513-0955 Panitumumab Vectibix 200.0 mg/10mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 10, 2006 Feb 28, 2010 No Longer Used
57894-0080-60 57894-0080 Lazertinib LAZCLUZE 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 20, 2024 In Use
67184-0531-02 67184-0531 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Feb 13, 2023 In Use
00069-0197-30 00069-0197 dacomitinib Vizimpro 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 4, 2018 In Use
63304-0095-11 63304-0095 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov 5, 2019 In Use
00378-7132-93 00378-7132 erlotinib hydrochloride Erlotinib Hydrochloride 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 Nov 30, 2022 No Longer Used
50742-0366-30 50742-0366 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Apr 27, 2023 In Use
54868-5447-00 54868-5447 Erlotinib Hydrochloride Tarceva 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 13, 2005 In Use
00378-7131-93 00378-7131 erlotinib hydrochloride Erlotinib Hydrochloride 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 Nov 30, 2022 No Longer Used
00310-1350-95 00310-1350 Osimertinib Tagrisso 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Mar 15, 2019 In Use
00093-7664-56 00093-7664 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 In Use
66733-0948-23 66733-0948 Cetuximab Erbitux 2.0 mg/mL Immunotherapy Monoclonal Antibody EGFR Intravenous Feb 12, 2004 In Use
00597-0137-30 00597-0137 Afatinib Gilotrif 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 9, 2013 In Use
57894-0080-90 57894-0080 Lazertinib LAZCLUZE 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 20, 2024 In Use
55513-0954-01 55513-0954 Panitumumab Vectibix 100.0 mg/5mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 10, 2006 In Use
68382-0913-16 68382-0913 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Apr 30, 2020 In Use
50242-0063-01 50242-0063 Erlotinib Hydrochloride Tarceva 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Apr 30, 2005 In Use
50242-0062-01 50242-0062 Erlotinib Hydrochloride Tarceva 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Apr 30, 2005 In Use

Found 11765 results — Export these results